VRG Therapeutics Zrt. and its subsidiaries are a technology-focused biotechnology group whose drug development platform combines artificial intelligence with laboratory processes to develop next-generation therapies.<\/p>\n\n\n\n
Our mission is to develop new therapeutic solutions that have previously proved unattainable using conventional drug development approaches.<\/p>\n\n\n\n
Our core activity is the development of natural and synthetic mini-protein-based drug candidates, which we create using directed evolution technology. In addition to mini-protein technology, there are two other areas of research which we are pursuing through separate companies. CREATe Therapeutics is working on a gene therapy that could be switched on and off using a drug-like molecule, whilst Novamigra Therapeutics is seeking a solution for the prevention of migraine using a combination of drugs.<\/p>\n\n\n\n
With investment support from the Sz\u00e9chenyi Funds, several of the company\u2019s research projects have reached the proof-of-concept (PoC) stage. One key development has moved a step closer to clinical trials through the involvement of a strategic co-development partner and progress made in the FDA\u2019s pre-IND process.<\/p>\n\n\n\n